Contributions
Abstract: EP1702
Type: Poster Sessions
Abstract Category: Therapy - Symptomatic treatment
Background: Fampridine is used to improve walking in patients with multiple sclerosis (PwMS). It has been shown to improve other measures such as manual functions and balance. Little is known about its effect on patients selected activities of daily living (ADL). We assessed the effect of fampridine on patients' self-perception on performance in everyday living using The Canadian occupational Performance Measure (COPM).
Methods: We included 102 patients suggested to start fampridine treatment by their treating physicians. The 10MWT was performed along with COPM before and after the initial 14 days fampridine trial. We defined responders on all the tests if at least 20% improvement was recorded between the two measures. Chi-square test was used to evaluate the distribution of responders and non-responders on COPM in relation to responders on 10MWT and gender. Additionally we correlated changes in 10MWT and COPM with the age and EDSS.
Results: In total, 100 PwMS (70 females, 30 males, mean age 51±11 years and EDSS 5.6±1) completed the study. The mean initial 10MWT time was 25.1±42.7, compared to 18.3±37.8 at reassessment (response rate of 78.4%). The average initial COPM-P (performance) score was 4.6 ± 1.5 compared to 6.1± 1.8 at reassessment (39.2% response rate). The average initial COPM-S (satisfaction) score was 6.1± 1.8 with the score of 6.5±1.9 at reassessment (44.1% response rate).
Males were more likely to respond on 10MWT (p=0.02). No differences were observed in responsiveness on COPM between the genders. We observed negative correlation between the patients' age and improvement on 10MWT (p=0.026). Correlations for COPM were not significant. EDSS score did not correlate with 10MWT nor COPM improvements. Patients who responded on 10MWT were more likely to respond also on COPM-P (p=0.01) and COPM-S (p=0.01). The improvements in COPM-P and COPM-S correlated well with the improvements in gait speed (p=0.002 and p=0.006).
Conclusions: Younger patients and males might benefit more from fampridine treatment in terms of gait regardless of the EDSS score. In certain patients with substantial improvement on 10MWT after initial 14 days fampridine trial improvement of meaningful and self-chosen ADL can also be expected.
Disclosure: The study was not funded by an external sponsor.
Disclosures:
Gregor Brecl Jakob: Nothing to disclose
Jelka Janša: Nothing to disclose
Andrej Martić: Nothing to disclose
Saša Alagić: Nothing to disclose
Saša Šega Jazbec: Nothing to disclose
Uroš Rot: Nothing to disclose
Alenka Horvat Ledinek: Nothing to disclose
Abstract: EP1702
Type: Poster Sessions
Abstract Category: Therapy - Symptomatic treatment
Background: Fampridine is used to improve walking in patients with multiple sclerosis (PwMS). It has been shown to improve other measures such as manual functions and balance. Little is known about its effect on patients selected activities of daily living (ADL). We assessed the effect of fampridine on patients' self-perception on performance in everyday living using The Canadian occupational Performance Measure (COPM).
Methods: We included 102 patients suggested to start fampridine treatment by their treating physicians. The 10MWT was performed along with COPM before and after the initial 14 days fampridine trial. We defined responders on all the tests if at least 20% improvement was recorded between the two measures. Chi-square test was used to evaluate the distribution of responders and non-responders on COPM in relation to responders on 10MWT and gender. Additionally we correlated changes in 10MWT and COPM with the age and EDSS.
Results: In total, 100 PwMS (70 females, 30 males, mean age 51±11 years and EDSS 5.6±1) completed the study. The mean initial 10MWT time was 25.1±42.7, compared to 18.3±37.8 at reassessment (response rate of 78.4%). The average initial COPM-P (performance) score was 4.6 ± 1.5 compared to 6.1± 1.8 at reassessment (39.2% response rate). The average initial COPM-S (satisfaction) score was 6.1± 1.8 with the score of 6.5±1.9 at reassessment (44.1% response rate).
Males were more likely to respond on 10MWT (p=0.02). No differences were observed in responsiveness on COPM between the genders. We observed negative correlation between the patients' age and improvement on 10MWT (p=0.026). Correlations for COPM were not significant. EDSS score did not correlate with 10MWT nor COPM improvements. Patients who responded on 10MWT were more likely to respond also on COPM-P (p=0.01) and COPM-S (p=0.01). The improvements in COPM-P and COPM-S correlated well with the improvements in gait speed (p=0.002 and p=0.006).
Conclusions: Younger patients and males might benefit more from fampridine treatment in terms of gait regardless of the EDSS score. In certain patients with substantial improvement on 10MWT after initial 14 days fampridine trial improvement of meaningful and self-chosen ADL can also be expected.
Disclosure: The study was not funded by an external sponsor.
Disclosures:
Gregor Brecl Jakob: Nothing to disclose
Jelka Janša: Nothing to disclose
Andrej Martić: Nothing to disclose
Saša Alagić: Nothing to disclose
Saša Šega Jazbec: Nothing to disclose
Uroš Rot: Nothing to disclose
Alenka Horvat Ledinek: Nothing to disclose